A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia

Journal of Clinical Lipidology

Volumn 1, Issue 6, 2007, Pages 634-639

  Chastain, Lisa M ^a,c   Bain, Amy M ^a,c   Edwards, Krystal L ^a,c   Bedimo, Roger ^b,c   Busti, Anthony J ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c North Texas Veterans Health Care System   (United States)

Author keywords

Antiretroviral therapy; Dyslipidemia; Ezetimibe; Human immunodeficiency virus; Hydroxymethylglutaryl Coenzyme A reductase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFECTION CONTROL; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 36849078230     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.10.003     Document Type: Article

References (34)

1. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the Infectious Disease Society of America and the adult Aids Clinical Trials Group. Clin Infect Dis 37 (2003) 613-627
2. Tsiodras S., Mantzoros C., Hammer S., and Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 160 (2000) 2050-2056
3. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63 (2003) 2555-2574
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults final report. Circulation 110 (2004) 227-239
5. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 10 (2006), Department of Health and Human Services 1-113. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf Accessed June 16, 2007
6. Fichtenbaum C., and Gerber J.G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41 (2002) 1195-1211
7. Zetia. [package insert] (2006), Merck/Schering-Plough Pharmaceuticals, North Wales, PA
8. Altmann S.W., Davis Jr. H.R., Zhu L.J., et al. Niemann-Pick C1 Like 1 Protein is critical for intestinal absorption. Science 303 (2004) 1201-1204
9. Knopp R.H., Gitter H., Truitt T., Bays H., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
10. Dujovne C.A., Ettinger M.P., McNeer J.F., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
11. Gagné C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
12. Nutescu E., and Shapiro N. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 23 (2003) 1463-1474
13. Coll B., Aragonés G., Parra S., Alonso-Villaverde C., and Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 20 (2006) 1675-1677
14. Negredo E., Moltó J., Puig J., et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidemia in HIV-infected patients with poor response to statins. AIDS 20 (2006) 2159-2164
15. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 21 (2005) 1-6
16. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
17. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study. AIDS 17 (2003) 1179-1193
18. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (2003) 2978-2982
19. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., and Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74 (1992) 1045-1052
20. Feingold K.R., Krauss R.M., Pang M., Doerrler W., Jensen P., and Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 76 (1993) 1423-1427
21. Périard D., Telenti A., Sudre P., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100 (1999) 700-705
22. Constans J., Pellegrin J.L., Peuchant E., et al. High plasma lipoprotein (a) in HIV-positive patients. Lancet 341 (1993) 1099-1100
23. Stein J.H., Klein M.A., Bellehumeur J.L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104 (2001) 257-262
24. Austin M.A., King M.C., Vranizan, and Krauss R.M. Atherogentic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
25. Kwiterovich P.O. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86 suppl (2000) 5L-10L
26. Tabib A., Greenland T., Mercier I., Loire R., and Mornex J.F. Coronary lesions in young HIV-positive patients at necropsy. Lancet 340 (1992) 730
27. Capron L., Kim Y.U., Laurian C., Bruneval P., and Fiessinger J.N. Atheroembolism in HIV-positive individuals. Lancet 340 (1992) 1039-1040
28. Paton P., Tabib A., Loire R., and Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144 (1993) 225-231
29. Constans J., Marchand J.M., Conri C., et al. Asymptomatic atherosclerosis in HIV-positive patients: a case-control ultrasound study. Ann Med 27 (1995) 683-685
30. Henry K., Melroe H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351 (1998) 1328
31. Behrens G., Schmidt H., Meyer D., Stoll M., and Schmidt R.E. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1958
32. Eriksson U., Opravil M., Amann F.W., and Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?. AIDS 12 (1998) 2079-2080
33. Flynn T.E., and Bricker L.A. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 131 (1999) 458
34. Friis-Møller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003